Trials / Completed
CompletedNCT04421339
Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- The University of Texas Health Science Center, Houston · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy of exogenous melatonin in improving sleep quality in HD gene carriers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Melatonin | Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over. |
| OTHER | Placebo | Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over. |
Timeline
- Start date
- 2021-01-22
- Primary completion
- 2022-09-16
- Completion
- 2022-09-16
- First posted
- 2020-06-09
- Last updated
- 2023-05-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04421339. Inclusion in this directory is not an endorsement.